Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guaifenesin SCHEMBL29759010 | 1.00 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL31161209 | 1.00 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL160234 | 1.00 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL4322 | 1.00 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL4894727 | 0.98 | CYP1A2 (0.96) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL2459821 | 0.98 | CYP1A2 (0.96) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL28898302 | 0.92 | CYP1A2 (0.84) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL28062894 | 0.92 | CYP1A2 (0.84) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| SCHEMBL29941729 | 0.90 | LMNA (0.82) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| SCHEMBL2328960 | 0.90 | LMNA (0.82) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16864 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-12629422-B2 | Agave syrup formulation or suspension for active pharmaceutical agents | GENEXA INC. (US) | 2026-05-19 | — | — | US | claimed |
| EP-4734952-A1 | ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES | Fertin Pharma A/S (DK) | 2026-05-06 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260049268-A1 | IN VITRO CELL CULTURE MUCUS SYSTEMS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-02-19 | — | — | US | claimed |
| US-12551439-B2 | Flowpack for oral delivery of active ingredients | FERTIN PHARMA A/S (DK) | 2026-02-17 | — | — | US | claimed |
| EP-4687840-A1 | THERAPEUTIC LIQUID COMPOSITIONS | Kenvue Brands LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4687841-A1 | THERAPEUTIC SUSPENSION COMPOSITIONS | Kenvue Brands LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| EP-0180597-A1 | COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS. | SUNSHINE ABRAHAM (US) | 1986-05-14 | — | — | EP | claimed |
| US-4576645-A | Whipped gel composition | BLOCK DRUG CO., INC. (US) | 1986-03-18 | — | — | US | claimed |
| WO-1985004589-A1 | COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | SUNSHINE ABRAHAM | 1985-10-24 | — | — | WO | claimed |
| EP-0147780-A2 | Drug delivery device | MERCK & CO. INC. (US) | 1985-07-10 | — | — | EP | claimed |
| EP-0058987-B1 | PROCESS FOR THE PREPARATION OF GUAIACOL GLYCERYL ETHER | Degussa Aktiengesellschaft (DE) | 1985-06-12 | — | — | EP | claimed |
| EP-0105361-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1984-04-18 | — | — | EP | claimed |
| WO-1983003541-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | UNIV GEORGIA RES FOUND (US) | 1983-10-27 | — | — | WO | claimed |
| US-4390732-A | Process for the production of guaiacol glycerine ether | DEGUSSA AG (DE) | 1983-06-28 | — | — | US | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| US-3968147-A | COORDINATION CATALYST | MONSANTO COMPANY (US) | 1976-07-06 | — | — | US | claimed |